Wilmington, DE -- (SBWIRE) -- 02/19/2014 -- -- Equity Profile Report expands its NYSE Active Stock Weekly Watch List adding Johnson & Johnson (NYSE:JNJ) and Morgan Stanley (NYSE:MS).
Johnson & Johnson (NYSE:JNJ) a company that together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide is currently up (+0.17%) on 1,615,272 shares traded after Johnson & Johnson's Cordis entered into an agreement with TriReme Medical that grants the co exclusive distribution rights for the Chocolate PTA Balloon Catheter. Johnson & Johnson (NYSE:JNJ) is currently up (+22.83%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NYSE Active Stock Watch List.
Click Here to find out what other Investors are saying about Johnson & Johnson (NYSE:JNJ)
Morgan Stanley (NYSE:MS) a financial holding company that provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide is currently down (-0.56%) on 3,042,174 shares traded. Morgan Stanley (NYSE:MS) is currently down (-12.44%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NYSE Active Stock Watch List.
Click Here to find out what other Investors are saying about Morgan Stanley (NYSE:MS)
Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Equityprofilereport.com
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.
Equity Profile Report